Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • When typing in this field, a list of search results will appear and be automatically updated as you type.

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

sweelin® Approved in Singapore as a Food Additive expanding Amai Proteins' Regulatory Footprint into Asia
  • APAC - English


News provided by

Amai Proteins

25 May, 2026, 11:00 IDT

Share this article

Share toX

Share this article

Share toX

Amai Proteins has achieved a major regulatory milestone with the Singapore Food Agency (SFA) approval of sweelin®, its flagship sweet protein, for use as a sweetening agent in food and beverage products.

sweelin® is a next-generation sweet protein that enables significant sugar reduction and replaces conventional sweeteners with a protein-based alternative, designed to deliver superior clean taste, competitive cost, and improved formulation performance.

REHOVOT, Israel, May 25, 2026 /PRNewswire/ -- Amai Proteins announces a major regulatory milestone for sweelin®, its flagship sweet protein, with approval from the Singapore Food Agency (SFA) for use as a sweetening agent in food and beverage products. Following the product's FDA GRAS approval in the United States, this achievement marks Amai's expansion into Asia and reinforces growing global regulatory momentum for sweelin®.

sweelin® is a next-generation sweet protein developed to significantly reduce sugar while replacing conventional sweeteners with a sweet protein that delivers clean taste, strong formulation performance, sustainability, and competitive pricing.  Additionally, sweelin® can be labeled as "Serendipity Berry Sweet Protein" in the US, supporting consumer-friendly ingredient claims and aligning with the growing demand for Clean-Label and GLP-1-friendly products.

Singapore has established itself as a global Food Technology Innovation leader with programs including its "30 by 30" initiative. These programs aim to produce 30% of the country's nutritional needs locally by 2030.  Advanced and sustainable food technologies and innovation, with Precision Fermentation and Alternative Proteins are key drivers of this strategy.

As a sweet protein produced via precision fermentation, sweelin® is strongly aligned with this strategic vision. With this SFA approval, sweelin® becomes the first precision fermentation-derived sweet protein approved in Singapore.  Once the approval is officially published, Amai Proteins will be positioned to accelerate its commercial activities and expand engagement with food and beverage manufacturers across Singapore and the Asia-Pacific region.

This milestone adds to several significant achievements for sweelin®:

  • FDA GRAS Approval in the United States — In February 2026, sweelin® received Generally Recognized as Safe (GRAS) status from the U.S. FDA for use as a general sweetener, establishing a strong regulatory foundation for global expansion.
  • First Clinical Trial Completed on a Sweet Protein — Amai Proteins completed a world's first clinical study demonstrating that sweelin® does not affect blood glucose, insulin, or GLP-1 levels.

Together, these achievements position sweelin® as a differentiated, great tasting, scalable, and consumer-aligned protein sweetener solution for the rapidly growing market for healthier food and beverages.

"Receiving regulatory approval for sweelin® in Singapore is a defining milestone for Amai Proteins" said Amir Guttman, CEO of Amai Proteins. "Singapore continues to demonstrate global leadership in food innovation through its forward-looking regulatory framework. We are honored that sweelin® is the first precision fermentation-derived sweet protein approved in this ecosystem. This approval validates our regulatory strategy and creates exciting opportunities for commercialization throughout Singapore and the Asia-Pacific region." 

Amai Proteins is actively engaging with strategic partners and investors across APAC to support commercial rollout and scale-up activities following the regulatory milestone.

About Amai Proteins

Amai Proteins develops, scales and commercializes proprietary sweet proteins for the food, beverage, and dietary supplement industries. The company's technology platform combines precision fermentation and advanced food technology to develop scalable, high-performance and great tasting protein ingredients.

Amai's lead product, sweelin®, is a monellin-based sweet protein inspired by the serendipity berry and is on average 3,000 times sweeter than sugar on a weight basis. The product is designed for stability, affordability, and compatibility with industrial food processing applications.

Produced through precision fermentation, sweelin® can be used in a wide variety of food & beverages, confectionery, chewing gum, condiments, and dietary supplements. Amai works with leading food and supplement manufacturers to enable up to 70% sugar reduction without compromising taste, cost, or sustainability.

For more information:

Dr. Amir Guttman, CEO, Amai Proteins
[email protected] 

SOURCE Amai Proteins

Modal title

Also from this source

sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization

With this regulatory milestone, Amai Proteins can now move quickly to run product trials and accelerate sales and market adoption with U.S. Food and...

More Releases From This Source

Explore

Food & Beverages

Food & Beverages

Health Care & Hospitals

Health Care & Hospitals

Beverages

Beverages

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.